TY - JOUR
T1 - Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
AU - Friedrich, Michael
AU - Jasinski-Bergner, Simon
AU - Lazaridou, Maria-Filothei
AU - Subbarayan, Karthikeyan
AU - Massa, Chiara
AU - Tretbar, Sandy
AU - Mueller, Anja
AU - Handke, Diana
AU - Biehl, Katharina
AU - Bukur, Jürgen
AU - Donia, Marco
AU - Mandelboim, Ofer
AU - Seliger, Barbara
PY - 2019/10
Y1 - 2019/10
N2 - Immunotherapy aims to activate the immune system to fight cancer in a very specific and targeted manner. Despite the success of different immunotherapeutic strategies, in particular antibodies directed against checkpoints as well as adoptive T-cell therapy, the response of patients is limited in different types of cancers. This attributes to escape of the tumor from immune surveillance and development of acquired resistances during therapy. In this review, the different evasion and resistance mechanisms that limit the efficacy of immunotherapies targeting tumor-associated antigens presented by major histocompatibility complex molecules on the surface of the malignant cells are summarized. Overcoming these escape mechanisms is a great challenge, but might lead to a better clinical outcome of patients and is therefore currently a major focus of research.
AB - Immunotherapy aims to activate the immune system to fight cancer in a very specific and targeted manner. Despite the success of different immunotherapeutic strategies, in particular antibodies directed against checkpoints as well as adoptive T-cell therapy, the response of patients is limited in different types of cancers. This attributes to escape of the tumor from immune surveillance and development of acquired resistances during therapy. In this review, the different evasion and resistance mechanisms that limit the efficacy of immunotherapies targeting tumor-associated antigens presented by major histocompatibility complex molecules on the surface of the malignant cells are summarized. Overcoming these escape mechanisms is a great challenge, but might lead to a better clinical outcome of patients and is therefore currently a major focus of research.
KW - Immune escape
KW - Immunotherapy
KW - MHC
KW - Resistance
KW - TIMO XIV
KW - Tumor
KW - HLA-G Antigens/physiology
KW - Tumor Escape
KW - Immunotherapy/methods
KW - Humans
KW - Histocompatibility Antigens Class I/immunology
KW - Neoplasms/therapy
KW - Antigen Presentation
KW - Programmed Cell Death 1 Receptor/antagonists & inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85074003895&partnerID=8YFLogxK
U2 - 10.1007/s00262-019-02373-1
DO - 10.1007/s00262-019-02373-1
M3 - Review
C2 - 31375885
SN - 0340-7004
VL - 68
SP - 1689
EP - 1700
JO - Cancer immunology, immunotherapy
JF - Cancer immunology, immunotherapy
IS - 10
ER -